Effect of epalrestat on liver injury in type 2 diabetic rats

doi:10.3969/j.issn.1006-7795.2017.02.021

Abstract

Abstract: Objective This study investigated the effect of epalrestat on liver injury in rats with type 2 diabetic mellitus (T2DM). Methods SD rats were fed with high-fat and high-sucrose diet for four weeks, then 45 mg·kg^-1 Streptozotocin (STZ) was injected intraperitoneally to make the animal model of type 2 diabetes. Diabetic rats were divided into two groups as the model group and the epalrestat group (100 mg·kg^-1), another 12 normal SD rats were served as the control group. The diabetic rats were treated with or without epalrestat by gavaging for 8 weeks. Body weight, food and water intake, blood glucose level, blood lipids were measured; liver function, liver pathological changes and oxidative stress were examined. Immunohistochemistry of α-smooth muscle actin (α-SMA)and transforming growth factor-β1 (TGF-β1) were conducted. Results Compared with the model group, epalrestat could reduce the concentration of fasting plasma glucose and blood lipids. The index for liver condition and oxidative stress were down regulated. Pathological examination showed that lesions of hepatic inflammation and fibrosis were significantly alleviated. The expressions of α-SMA and TGF-β1 were markedly reduced in liver tissues of type 2 diabetic rats with the treatment of epalrestat. Conclusion Epalrestat could alleviate liver inflammation and hepatic fibrosis of rats with T2DM via anti-oxidative stress and inhibiting the activation of hepatic stellate cell.

Key words: epalrestat, type 2 diabetic mellitus, oxidative stress, hepatic fibrosis

CLC Number:

Zhao Yuerong, Hou Biyu, Liu Chenge, Wang Xiaobo, Du Guanhua, Zhang Li, Guan Shuyu. Effect of epalrestat on liver injury in type 2 diabetic rats[J]. Journal of Capital Medical University, 2017, 38(2): 268-276.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.02.021

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I2/268

References

[1] World Health Organization Global report on diabetes[R]. Geneva:World Health Organization,2016.
[2] Bhatt H B, Smith R J. Fatty liver disease in diabetes mellitus[J]. Hepatobiliary Surg Nutr, 2015, 4(2):101-108.
[3] Davis T M, Peters K E, Bruce D G, et al. Prevalence, incidence, and prognosis of hepatobiliary disease in community-based patients with type 2 diabetes: the Fremantle Diabetes Study[J].J Clin Endocrinol Metab, 2012, 97(5):1581-1588.
[4] 周玉, 张明. 依帕司他治疗糖尿病周围神经病变的效果分析[J]. 糖尿病新世界, 2016, 19(18):33-34.
[5] 马开颜,李娜.依帕司他片治疗糖尿病肾病43例疗效观察[J].陕西医学杂志,2016, 6(3):380.
[6] Hotta N, Kawamori R, Fukuda M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy[J]. Diabet Med, 2012, 29(12):1529-1533.
[7] Sato K, Yama K, Yu M, et al. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation[J]. Redox Biol, 2013, 2:15-21.
[8] Li Z Y, Deng X L, Huang W H, et al. Lignans from the bark of Eucommia ulmoides inhibited Ang-Ⅱstimulated extracellular matrix biosynthesis in mesangial cells[J]. Chin Med, 2014, 9(1):8.
[9] 强桂芬,张莉,宣琪,等.二甲双胍对2型糖尿病大鼠肝纤维化形成的影响[J].药学学报,2010,45(6):801-806.
[10] 赵世印,邱华,贺琴,等.绞股蓝皂苷对2型糖尿病合并非酒精性脂肪性肝病模型大鼠肝纤维化影响[J].医药导报,2014,33(2):156-159.
[11] 郭翼华, 项嘉亮, 黄碧云. 氧化应激与糖尿病并发症发生的相关性研究[J]. 中国基层医药, 2010, 17(17):2352-2353.
[12] Ashraf H, Zare S. Preventive effects of aqueous extract of berberis integerrima bge. root on liver injury induced by diabetes mellitus (Type 1) in rats[J].Iran J Pharm Res, 2015, 14(1):335-343.
[13] Lee K S, Lee S J, Park H J, et al.Oxidative stress effect on the activation of hepatic stellate cells[J].Yonsei Med J,2001,42(1):1-8.
[14] Babalola O, Mamalis A, Lev-Tov H, et al. NADPH oxidase enzymes in skin fibrosis:molecular targets and therapeutic agents[J].Arch Dermatol Res,2014,306(4):313-330.
[15] Kang Y S, Song H K, Lee M H, et al. Visfatin is unregulated in type 2 diabetic rats and targets renal ceus[J].Kidney Int,2010,78(2):170-181.
[16] Ohmura C, Watada H, Azuma K, et al. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes[J]. Endocr J, 2009, 56(1):149-156.
[17] Li Q R, Wang Z, Zhou W, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway[J]. Neural Regen Res, 2016, 11(2):345-351.
[18] 夏海珊, 陈少茹, 钟月春,等. 肝纤维化的发病机制和药物治疗现况[J]. 中国医药导报, 2014, 11(18):162-165.
[19] 王静, 何方平, 娜丽玛,等. 2型糖尿病发生肝纤维化的相关危险因素分析[J]. 中华糖尿病杂志, 2015,7(3):156-160.
[20] Hernandez-Gea V, Friedman S L. Pathogenesis of liver fibrosis[J].Annu Rev Pathol,2011,6:425-456.
[21] Pinzani M, Maciasbarragan J. Update on the pathophysiology of liver fibrosis[J]. Expert Rev Gastroenterol Hepatol, 2010, 4(4):459-472.
[22] Chen H N, Fan S, Weng C F. Down-regulation of TGF-beta1 and leptin ameliorates thioacetamide-induced liver injury in lipopolysaccharide-primed rats[J]. J Endotoxin Res, 2007, 13(3):176-188.
[23] Li X, Shen Y, Lu Y, et al. Amelioration of bleomycin-induced pulmonary fibrosis of rats by an aldose reductase inhibitor, epalrestat[J]. Korean J Physiol Pharmacol,2015,19(5):401-411.
[24] Jiang T, Che Q I, Lin Y, et al. Aldose reductase regulates TGF-β1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells[J]. Nephrology, 2006, 11(2):105-112.
[25] 张玉姣.肝星状细胞和枯否细胞在肝纤维化过程中的相互作用[D]. 长春: 吉林大学, 2015.
[26] Ji H Y, Sang C K, Kim K M, et al. Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress[J]. Eur J Pharmacol, 2016, 783(15):92-102.
[27] 邵佳亮,胡国信,郑洁,等. 羟基喜树碱对肝纤维化大鼠肝组织Bax、Bcl-2基因和α-SMA蛋白表达及肝纤维化的影响[J]. 第二军医大学学报, 2014, 35(4):399-405.